Rasburicase is a recombinant urate-oxidase enzyme produced with the aid of a genetically changed <i>Saccharomyces cerevisiae</i> strain. The cDNA coding for rasburicase become cloned from a pressure of _Aspergillus flavus_.
Drugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)
Rasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).